Moreover, XPO1 is frequently overexpressed in DLBCL and correlates with poor prognosis, highlighting its significance as a therapeutic target in this aggressive lymphoma subtype [173]. The gene discussed is XPO1; the disease is diffuse large B-cell lymphoma.